A Phase I Study of Pazopanib in Adult Patients With Liver Cancer
- Registration Number
- NCT00370513
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown. This study is designed to evaluate the safety, tolerability and best dose of pazopanib to be given to patient with liver cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Pazopanib Arm pazopanib Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
- Primary Outcome Measures
Name Time Method Adverse events (AEs) and changes in vital signs and laboratory values. A dose regimen where no more than 1 out of 6 subjects experience a dose-limiting toxicity (DLT) will define the maximum tolerated dose (MTD). throughout the study
- Secondary Outcome Measures
Name Time Method Various pharmacokinetic parametersAlpha-fetoprotein (AFP) measurements and scans throughout the study
Trial Locations
- Locations (1)
GSK Investigational Site
🇨🇳Taipei, Taiwan